Experience
Advise the world’s largest family foundation on strategy and patent portfolio development and assist with various investments and licensing matters, including assisting the Foundation’s subsidiary, Gates Ag One with developing intellectual property for programs aimed at improving photosynthesis and nitrogen use efficiency in plants.
Counsel Genentech, the world’s most successful biotechnology company and part of the Roche family of companies, on developing the company’s strategy for its multibillion-dollar portfolios, including blockbuster cancer drugs Kadcyla, Perjeta, Gazyva, Tecentriq, and Polivy.
Represent Inari, a plant breeding technology company working to build a more sustainable global food system through its SEEDesign platform, for patent prosecution of AI and gene editing technologies.
Counsel Juno Therapeutics, a biopharmaceutical company focused on cancer cell therapy, in the IP due diligence that was the basis for a significant portion of the valuation for its $9 billion acquisition by Celgene (now Bristol-Myers Squibb). We continue to lead strategy on the Juno portfolio following the acquisition.
Advise Ohalo Genetics on patent strategy for technology related to novel breeding systems in plants. Ohalo’s Boosted Breeding technology aims to accelerate variety development, produced higher yielding corps, and allows production of true seed in vegetatively propagated crops.
Direct patent prosecution strategy for the gene editing technologies developed by Meiogenix, that are used to unlock the natural genetic diversity of wild crops.
Represent Attralus, a clinical stage biotech company on intellectual property strategy and patent prosecution for its patent portfolio that covers diagnostics for amyloid-related diseases and large molecules used to treat amyloid-related diseases.
Patent counsel for Sonoma Therapeutics, an emerging clinical-stage company that focuses on cell therapies to treat inflammatory diseases.